Spesolimab Efficacy Data

Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.